BACKGROUND:Heart failure (HF) is a disease commonly associated with coronary artery disease. Most risk models for HF development have focused on patients with acute myocardial infarction. The Prevention of Events with Angiotensin-Converting Enzyme Inhibition population enabled the development of a risk model to predict HF in patients with stable coronary artery disease and preserved ejection fraction. METHODS AND RESULTS: In the 8290, Prevention of Events with Angiotensin-Converting Enzyme Inhibition patients without preexisting HF, new-onset HF hospitalizations, and fatal HF were assessed over a median follow-up of 4.8 years. Covariates were evaluated and maintained in the Cox regression multivariable model using backward selection if P<0.05. A risk score was developed and converted to an integer-based scoring system. Among the Prevention of Events with Angiotensin-Converting Enzyme Inhibition population (age, 64+/-8; female, 18%; prior myocardial infarction, 55%), there were 268 cases of fatal and nonfatal HF. Twelve characteristics were associated with increased risk of HF along with several baseline medications, including older age, history of hypertension, and diabetes. Randomization to trandolapril independently reduced the risk of HF. There was no interaction between trandolapril treatment and other risk factors for HF. The risk score (range, 0 to 21) demonstrated excellent discriminatory power (c-statistic 0.80). Risk of HF ranged from 1.75% in patients with a risk score of 0% to 33% in patients with risk score >or=16. CONCLUSIONS: Among patients with stable coronary artery disease and preserved ejection fraction, traditional and newer factors were independently associated with increased risk of HF. Trandolopril decreased the risk of HF in these patients with preserved ejection fraction.
RCT Entities:
BACKGROUND:Heart failure (HF) is a disease commonly associated with coronary artery disease. Most risk models for HF development have focused on patients with acute myocardial infarction. The Prevention of Events with Angiotensin-Converting Enzyme Inhibition population enabled the development of a risk model to predict HF in patients with stable coronary artery disease and preserved ejection fraction. METHODS AND RESULTS: In the 8290, Prevention of Events with Angiotensin-Converting Enzyme Inhibition patients without preexisting HF, new-onset HF hospitalizations, and fatal HF were assessed over a median follow-up of 4.8 years. Covariates were evaluated and maintained in the Cox regression multivariable model using backward selection if P<0.05. A risk score was developed and converted to an integer-based scoring system. Among the Prevention of Events with Angiotensin-Converting Enzyme Inhibition population (age, 64+/-8; female, 18%; prior myocardial infarction, 55%), there were 268 cases of fatal and nonfatal HF. Twelve characteristics were associated with increased risk of HF along with several baseline medications, including older age, history of hypertension, and diabetes. Randomization to trandolapril independently reduced the risk of HF. There was no interaction between trandolapril treatment and other risk factors for HF. The risk score (range, 0 to 21) demonstrated excellent discriminatory power (c-statistic 0.80). Risk of HF ranged from 1.75% in patients with a risk score of 0% to 33% in patients with risk score >or=16. CONCLUSIONS: Among patients with stable coronary artery disease and preserved ejection fraction, traditional and newer factors were independently associated with increased risk of HF. Trandolopril decreased the risk of HF in these patients with preserved ejection fraction.
Authors: Eldrin F Lewis; Gervasio A Lamas; Eileen O'Meara; Christopher B Granger; Mark E Dunlap; Robert S McKelvie; Jeffrey L Probstfield; James B Young; Eric L Michelson; Katarina Halling; Jonas Carlsson; Bertil Olofsson; John J V McMurray; Salim Yusuf; Karl Swedberg; Marc A Pfeffer Journal: Eur J Heart Fail Date: 2006-12-21 Impact factor: 15.534
Authors: Hossein Bahrami; David A Bluemke; Richard Kronmal; Alain G Bertoni; Donald M Lloyd-Jones; Eyal Shahar; Moyses Szklo; João A C Lima Journal: J Am Coll Cardiol Date: 2008-05-06 Impact factor: 24.094
Authors: Eldrin F Lewis; Eric J Velazquez; Scott D Solomon; Anne S Hellkamp; John J V McMurray; Jasmine Mathias; Jean-Lucien Rouleau; Aldo P Maggioni; Karl Swedberg; Lars Kober; Harvey White; Anthony J Dalby; Gary S Francis; Faiez Zannad; Robert M Califf; Marc A Pfeffer Journal: Eur Heart J Date: 2008-02-28 Impact factor: 29.983
Authors: Torbjørn Omland; Marc S Sabatine; Kathleen A Jablonski; Madeline Murguia Rice; Judith Hsia; Ragnhild Wergeland; Sverre Landaas; Jean L Rouleau; Michael J Domanski; Christian Hall; Marc A Pfeffer; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2007-06-29 Impact factor: 24.094
Authors: Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Beatriz Paradela-Dobarro; Lilian Grigorian-Shamagian; José M García-Acuña; Pablo Aguiar-Souto; Michel Jacquet-Hervet; María V Reino-Maceiras; Ezequiel Alvarez; José R González-Juanatey Journal: Cardiovasc Diabetol Date: 2012-08-21 Impact factor: 9.951
Authors: Jimeng Sun; Jianying Hu; Dijun Luo; Marianthi Markatou; Fei Wang; Shahram Edabollahi; Steven E Steinhubl; Zahra Daar; Walter F Stewart Journal: AMIA Annu Symp Proc Date: 2012-11-03
Authors: Joost P van Melle; Mariska Bot; Peter de Jonge; Rudolf A de Boer; Dirk J van Veldhuisen; Mary A Whooley Journal: Diabetes Care Date: 2010-09 Impact factor: 19.112
Authors: Duncan J Campbell; Jithendra B Somaratne; Alicia J Jenkins; David L Prior; Michael Yii; James F Kenny; Andrew E Newcomb; Casper G Schalkwijk; Mary J Black; Darren J Kelly Journal: Cardiovasc Diabetol Date: 2011-09-19 Impact factor: 9.951
Authors: Regis R Lamberts; Shivanjali J Lingam; Heng-Yu Wang; Ilse A E Bollen; Gillian Hughes; Ivor F Galvin; Richard W Bunton; Andrew Bahn; Rajesh Katare; J Chris Baldi; Michael J A Williams; Pankaj Saxena; Sean Coffey; Peter P Jones Journal: Cardiovasc Diabetol Date: 2014-04-05 Impact factor: 9.951